Cargando…

Proteomic analysis of radioiodine-refractory differentiated thyroid cancer identifies CHI3L1 upregulation in association with dysfunction of the sodium-iodine symporter

Radioiodine refractory differentiated thyroid cancer (RR-DTC) is the main factor adversely affecting the overall survival rate of patients with thyroid cancer. The aim of the present study was to investigate the underlying molecular mechanism of pathogenesis of RR-DTC and to explore novel therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yunjie, Hu, Fengqiong, Deng, Jie, Huang, Xin, Zhou, Chunyan, Wu, Mengxue, Duan, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773326/ https://www.ncbi.nlm.nih.gov/pubmed/36589664 http://dx.doi.org/10.3892/ol.2022.13622

Ejemplares similares

The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF(V600E) Mutation
por: Anekpuritanang, Tauangtham, et al.
Publicado: (2021)

Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter
por: Kaneda-Nakashima, Kazuko, et al.
Publicado: (2022)

Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells
por: Xu, Shichen, et al.
Publicado: (2021)

Induction of Sodium/Iodide Symporter (NIS) Expression and Radioiodine Uptake in Non-Thyroid Cancer Cells
por: Liu, Zhi, et al.
Publicado: (2012)

Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine
por: Hutzen, Brian, et al.
Publicado: (2012)

Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake
por: Chung, Taemoon, et al.
Publicado: (2015)

Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
por: Plantinga, Theo S., et al.
Publicado: (2016)

Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter
por: Huang, R, et al.
Publicado: (2011)

Extracellular vesicles deliver sodium iodide symporter protein and promote cancer cell radioiodine therapy
por: Lee, Jin Hee, et al.
Publicado: (2022)

An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na(+)/I(−) Symporter Function in Radioiodine-Refractory Papillary Thyroid Cancer Cells
por: Singh, Thoudam Debraj, et al.
Publicado: (2023)

New! F-18-based PET/CT for sodium-iodine-symporter-targeted imaging!
por: Verburg, Frederik A., et al.
Publicado: (2020)

Mechanisms of Sodium/Iodide Symporter-Mediated Mammary Gland Iodine Compensation during Lactation
por: Fu, Min, et al.
Publicado: (2022)

Clinical Significance of Thyroid-Stimulating Hormone Receptor Gene Mutations and/or Sodium-Iodine Symporter Gene Overexpression in Indeterminate Thyroid Fine Needle Biopsies
por: Guan, Haixia, et al.
Publicado: (2018)

The glial fibrillary acidic protein promoter directs sodium/iodide symporter gene expression for radioiodine therapy of malignant glioma
por: LI, WEI, et al.
Publicado: (2013)

Enhancement of Natural Killer Cell Cytotoxicity by Sodium/Iodide Symporter Gene-Mediated Radioiodine Pretreatment in Breast Cancer Cells
por: Kim, Hae Won, et al.
Publicado: (2013)

A Steep Radioiodine Dose Response Scalable to Humans in Sodium Iodide Symporter (NIS) Mediated Radiovirotherapy for Prostate Cancer
por: Trujillo, Miguel A., et al.
Publicado: (2012)

Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS
por: Oh, Ji Min, et al.
Publicado: (2021)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Dietary Iodine Intake, Therapy with Radioiodine, and Anaplastic Thyroid Carcinoma
por: Besic, Nikola, et al.
Publicado: (2020)

Dimerization of the Sodium/Iodide Symporter
por: Thompson, Rebecca J., et al.
Publicado: (2019)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Decreased Expression of Thyroglobulin and Sodium Iodide Symporter Genes in Hashimoto's Thyroiditis
por: Popławska-Kita, Anna, et al.
Publicado: (2014)

Radioiodine treatment of differentiated thyroid cancer despite history of ‘iodine allergy’
por: Puchalski, Adam R, et al.
Publicado: (2014)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Biological implications of PTEN upregulation and altered sodium/iodide symporter intracellular distribution in resveratrol-suppressed anaplastic thyroid cancer cells
por: Xiong, Le, et al.
Publicado: (2020)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
por: Wadsley, Jon, et al.
Publicado: (2023)

Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter
por: Gao, Xiao-Feng, et al.
Publicado: (2014)

Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells
por: Chatterjee, Sushmita, et al.
Publicado: (2015)

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
por: Worden, Francis, et al.
Publicado: (2015)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
por: Chiapponi, Costanza, et al.
Publicado: (2021)

New approaches for patients with advanced radioiodine-refractory thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2022)

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
por: Nervo, Alice, et al.
Publicado: (2022)

Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system
por: Oh, Ji Min, et al.
Publicado: (2018)

Misdiagnosis of Paraganglioma by (123)I-mIBG Without Stable Iodine Blockade of Thyroidal Radioiodine Uptake
por: Chen Cardenas, Stanley M, et al.
Publicado: (2020)

Resveratrol Inhibits Sodium/Iodide Symporter Gene Expression and Function in Rat Thyroid Cells
por: Giuliani, Cesidio, et al.
Publicado: (2014)

Effect of Dimerization on the Dynamics of Neurotransmitter:Sodium Symporters
por: Gur, Mert, et al.
Publicado: (2017)

A comparison of thyroidal protection by iodine and perchlorate against radioiodine exposure in Caucasians and Japanese
por: Rump, A., et al.
Publicado: (2021)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_va7294jppq43rafog88v6vladc